AAAAAA

   
Results: 1-9 |
Results: 9
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines:In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide
Authors: Indrova, M Bubenik, J Simova, J Vonka, V Nemeckova, S Mendoza, L Reinis, M
Citation: M. Indrova et al., Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines:In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide, INT J MOL M, 7(1), 2001, pp. 97-100
Chemoimmunotherapy of cancer: Potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A
Authors: Indrova, M Bubenik, J Simova, J Bieblova, J Jandlova, T Smahel, M Vonka, V Glazman-Kusnierczyk, H Pajtasz-Piasecka, E Radzikowski, C Mikyskova, R
Citation: M. Indrova et al., Chemoimmunotherapy of cancer: Potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A, ONCOL REP, 8(6), 2001, pp. 1371-1374
Local cytokine treatment of HPV16-associated tumours results in inhibitionof their lung metastases
Authors: Mikyskova, R Bubenik, J Mendoza, L Vonka, V Smahel, M Simova, J Jandlova, T
Citation: R. Mikyskova et al., Local cytokine treatment of HPV16-associated tumours results in inhibitionof their lung metastases, CLIN EXP M, 18(7), 2001, pp. 581-587
Metastatic MHC class I-negative mouse cells derived by transformation withhuman papillomavirus type 16
Authors: Smahel, M Sobotkova, E Bubenik, J Simova, J Zak, R Ludvikova, V Hajkova, R Kovarik, J Jelinek, F Povysil, C Marinov, J Vonka, V
Citation: M. Smahel et al., Metastatic MHC class I-negative mouse cells derived by transformation withhuman papillomavirus type 16, BR J CANC, 84(3), 2001, pp. 374-380
Intratumoral IL-2 gene transfer improves the therapeutic efficacy of IL-12but not IL-18
Authors: Sobota, V Bubenik, J Simova, J Jandlova, T
Citation: V. Sobota et al., Intratumoral IL-2 gene transfer improves the therapeutic efficacy of IL-12but not IL-18, FOL BIOL, 46(5), 2000, pp. 191-193
Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80, molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines
Authors: Simova, J Reinis, M Sobota, V Capkova, J Bubenik, J Jandlova, T
Citation: J. Simova et al., Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80, molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines, FOL BIOL, 46(1), 2000, pp. 11-15
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16
Authors: Bubenik, J Simova, J Hajkova, R Sobota, V Jandlova, T Smahel, M Sobotkova, E Vonka, V
Citation: J. Bubenik et al., Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16, INT J ONCOL, 14(3), 1999, pp. 593-597
Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines
Authors: Rossner, P Bubenik, J Sobota, V Indrova, M Hajkova, R Mendoza, L Jandlova, T Simova, J
Citation: P. Rossner et al., Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines, FOL BIOL, 45(5), 1999, pp. 173-177
IL-2 gene-modified tumour vaccines: Monitoring of IL-2 levels in serum andperitoneal cavity of vaccinated mice
Authors: Indrova, M Pajtasz-Piasecka, E Jandlova, T Simova, J Bubenik, J Radzikowski, C
Citation: M. Indrova et al., IL-2 gene-modified tumour vaccines: Monitoring of IL-2 levels in serum andperitoneal cavity of vaccinated mice, FOL BIOL, 45(1), 1999, pp. 7-11
Risultati: 1-9 |